Five years of evidence deliver a reassuring message: GLP-1 medicines are not linked to major psychiatric harm. Research co-authored by Kavita Batra (Medicine), Jagdish Khubchandani from New Mexico State University, and colleagues found no increased risk of suicidal thoughts, depression, or other serious psychiatric outcomes in the general treated population. Published in Diabetology, the review has received national and international coverage from the American Diabetes Association’s DiabetesPro SmartBrief and Diabetes.co.uk. The clinical message is clear: unsupported safety concerns should not prevent patients from receiving effective treatment, while routine screening and closer monitoring remain essential for those with existing mental health vulnerabilities.